Brimonidine-D-tartrate

CAS: 70359-46-5

Ref. 3D-FB32174

Produktinformation

• Name: Brimonidine-D-tartrate
• Synonyme: (5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine L-tartrate, 5-Bromo-N-(4,5-Dihydro-1H-Imidazol-2-Yl)-6-Quinoxalinamine Tartrate, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine 2,3-dihydroxybutanedioate (1:1), 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine 2,3-dihydroxybutanedioate (salt), 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1), 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), Agn 190342Lf, Alphagan, Alphagan P, Brimonidine Purite, Brimonidine tartrate, Brominide tartrate, Mirvaso

Beschreibung

Brimonidine-D-tartrate is a synthetic, selective alpha 2-adrenergic receptor agonist that has been developed for use in the treatment of glaucoma. It is an ester prodrug that is hydrolyzed to form brimonidine, which binds to the alpha 2-adrenergic receptor and inhibits neurotransmitter release from nerve endings. This drug has been shown to be effective in vivo in humans, using a fluorescent derivative as a model system. Brimonidine-D-tartrate has also been shown to have neurotrophic properties, and can be used for the treatment of other conditions such as dry eye syndrome.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 442.22 g/mol
• Formel: C₁₅H₁₆BrN₅O₆
• Farbe/Form: White Powder
• InChl: InChI=1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
• InChI Key: InChIKey=QZHBYNSSDLTCRG-LREBCSMRSA-N
• SMILES: Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)[C@H](O)[C@@H](O)C(=O)O